Found it interesting that while Paxlovid has had greater success against #COVID19, Molnupiravir (& Remdesivir) might have more promise for future pandemics
QT:{{”
Not all RdRp inhibitors work the same way. In most cases, including with remdesivir, viruses incorporate the drug into the elongating RNA, and this brings the elongation process to a halt. Molnupiravir’s mechanism is different: elongation doesn’t stop when the enzyme incorporates the drug into viral RNA. Instead, the virus reuses molnupiravir-containing RNAs as template strands, and incorporates the wrong bases into new viral RNA when it re-encounters molnupiravir. Mutations accumulate over cycles, leading to ‘error catastrophe’ and viral death.
“}}
linkstream2 microblog 